Project Grant R43AI197370
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Blacksburg, VA, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Biotherapeutics, Inc. $314,363 on August 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop novel oral immunoregulatory therapeutics for Helicobacter pylori–induced bacterial gastritis. Biotherapeutics, Inc., a clinical-stage biotechnology company headquartered in Blacksburg, Virginia, will evaluate the therapeutic efficacy of a host-centered product candidate in regulating local and...
- The National Institute of Allergy and Infectious Diseases awarded $489,500 to Benaroya Research Institute at Virginia Mason on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify molecular mechanisms that inhibit CNS resident memory T cells driving neuroinflammation in multiple sclerosis. The project investigates CNS CD4+ tissue resident memory T cells (TRM) as a reservoir of autoreactive cells that sustains MS disease activity and resists...
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, awarded $300,000 to the University of Texas Southwestern Medical Center on September 10, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds development of immune checkpoint-engineered oligodendrocytes as a cell-based therapeutic approach for multiple sclerosis. The research builds on prior work demonstrating that immune...
- The National Institute of Allergy and Infectious Diseases awarded Syracuse University $137,429 on April 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop tolerogenic dendritic cell membrane-coated nanoparticles for precision multiple sclerosis therapy. The project addresses the development of protein-decorated rapamycin-encapsulated nanoparticles designed to selectively suppress central nervous system-infiltrated autoantigen-specific CD4+ T cells in...
- The National Institute of Allergy and Infectious Diseases awarded The Washington University $624,300 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate myelin and non-myelin immune responses in multiple sclerosis. The research characterizes T cell receptor (TCR) repertoire and specificity in MS patients through single-cell paired TCR sequencing, convergence algorithms, and antigen discovery platforms. The work applies unbiased TCR...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $347,976 on April 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate interleukin 33 signaling as a therapeutic target for multiple sclerosis. The research seeks to establish interleukin (IL)-33-induced amphiregulin as a mechanism to halt MS progression and promote remyelination. The award funds two primary aims: Aim 1 investigates IL-33-mediated...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $518,450 to Scripps Research Institute on June 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a targeted protein degradation strategy against botulinum neurotoxin. The research addresses the lack of approved therapeutics for botulism beyond the heptavalent antitoxin, which slows disease progression but cannot penetrate...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded Wake Forest University Health Sciences $502,528 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop next-generation protein neurotherapeutics for botulism poisoning. The award funds research into countermeasures against botulinum neurotoxins, which cause flaccid paralysis and currently lack a pharmacological antidote. Current...
- The National Institute of Allergy and Infectious Diseases awarded the University of Pittsburgh $762,086 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify signaling networks that contribute to TH17-mediated neuroinflammation in multiple sclerosis. The recipient will develop a comprehensive suite of mass spectrometry proteomics tools to characterize protein abundance and phosphorylation in pathogenic TH17 cells at the systems level using the...
- The National Institute of Allergy and Infectious Diseases awarded Baylor College of Medicine $798,854 on June 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop brain-penetrant molecular glue degraders targeting VAV1 as a therapeutic approach for multiple sclerosis. The research strategy encompasses three primary aims: optimizing lead VAV1 molecular glue degraders for enhanced potency, brain penetration, and favorable pharmacokinetic properties using...